Solutions

Respiratory Infections Portfolio Detection of highly transmissible respiratory pathogens

The BD MAXTM Portfolio of Respiratory assays

The efficiency and versatility offered by the BD MAX™ System and the Respiratory portfolio facilitate high volume molecular testing for rapid diagnosis and treatment.

Global infection
spread

Diagnostic
challenges

Value of
molecular testing

Global infection spread

  • Globally, every year there are an estimated 1 billion cases of seasonal influenza, of which 3 to 5 million are severe cases1
  • TB remains the world’s top infectious killer with 10 million contracting the disease each year and 1.5 million deaths2

Global pandemics occur when new strains occur of known respiratory viruses.

  • 2019 novel coronavirus (SARS-CoV-2) is a new strain that has not been previously identified in humans and is an international public health threat

Diagnostic challenges

Diagnosis of acute respiratory infections can be difficult

  • Clinical symptoms: A number of other viruses and bacteria cause similar symptoms so much of influenza-like illness is determined not to be influenza3
  • Management of testing need: Acute respiratory infections spread easily from person to person through the air or by direct or indirect contact. Seasonal or pandemic infection drives high volumes of testing and need for rapid diagnosis to direct isolation and treatment
  • Test result accuracy: Traditional respiratory tests can be less reliable and false positive or false negative results can occur4

Value of molecular testing

Rapid and accurate diagnosis is critical

  • Molecular viral testing with real-time PCR has high sensitivity
  • Molecular testing for TB provides timely results useful for high quality patient care, low contamination risk and ease of performance and speed5
  • Molecular testing is now available for SARS-CoV-2 to efficiently diagnose and inform patient

Meet the BD MAX™ Respiratory Portfolio:

 

BD SARS-CoV-2 Reagents
for BD MAX™ System 
  • SARS-CoV-2 (N1)
  • SARS-CoV-2 (N2)
VIASURE SARS-CoV-2 (N1+N2)
Real Time PCR Detection Kit 
for BD MAX™ 
  • SARS-CoV-2 (N1)
  • SARS-CoV-2 (N2)
VIASURE SARS-CoV-2 Variant
Real Time PCR Detection Kit
for BD MAX™
  • B.1.1.7 (Alpha) variant (69/70 deletion)
BD SARS-CoV-2/Flu
for BD MAX™ System
  • SARS-CoV-2 (N1 + N2)
  • Influenza A
  • Influenza B
VIASURE Flu A, Flu B & RSV
Real Time PCR Detection Kit
for BD MAX™ System
  • Influenza A
  • Influenza B
  • Human Respiratory Syncytial Viruses (RSV)
VIASURE SARS-CoV-2, Flu (A+B)
& RSV Real Time PCR Detection Kit
for BD MAX™ System
  • SARS-CoV-2 (N1)
  • SARS-CoV-2 (N2)
  • Influenza A
  • Influenza B
  • RSV
BD MAX™ MDR-TB
  • Mycobacterium tuberculosis complex (MTBC)
  • RIF resistance
  • INH resistance

Meet the BD MAX™ Portfolio of HAI assays

The BD MAX™ Portfolio of HAI assays enables your laboratory to:

  • Provide results for up to 24 specimens in less than 3 hours
  • Decrease hands-on time for laboratory technicians versus traditional methods
  • Limit the risk of potential errors and maintain chain of custody including sample transfers and manual manipulations
  • Control total cost of ownership by limiting indirect costs

Detection of Gram Negative pathogens

BD MAX™
Check-Points CPO assay
Screening for carbapenemase-producing organism (CPO) through the identification of the five most common carbapenemase genes:
  • KPC
  • OXA-48 (OXA-48 and OXA-48 like)
  • NDM
  • VIM/IMP
Check-Points [Check-Direct]
ESBL Screen for BD MAX™4
Screening for extended-spectrum beta-lactamase (ESBL) producing pathogenic enterobacteria, can be run in parallel with BD MAX™ Check-Points CPO to detect ESBLs and carbapenemases simultaneously:
  • CTX-M-1 group
  • CTX-M-2 group
  • CTX-M-9 group
  • SHV-ESBL

Detection of Gram Positive pathogens

BD MAX™
MRSA XT
Active surveillance of methicillin- resistant Staphylococcus aureus (MRSA) with Extended Detection Technology including mecA and mecC resistance
BD MAX™
StaphSR
Differentiation of S. aureus and MRSA with the same Extended Detection Technology as the BD MAX™ MRSA XT assay
BD MAX™
Cdiff
Detection of toxigenic Clostridioides difficile through the identification of toxin B gene (tcdB)
VIASURE VanR Real
Time PCR Detection
Kit for BD MAX™
Active surveillance of vancomycin-resistant enterococci through the detection of vanA and vanB genes

The BD MAX™ System is a single platform capable
of running BD and partner developed assays
as well as laboratory-developed tests

INH, isoniazid; MTBC, Mycobacterium tuberculosis complex; PCR, polymerase chain reaction; RIF, rifampicin; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TB, tuberculosis

1. World Health Organization. 8 Things to know about pandemic influenza. Available at: https://www.who.int/news-room/feature-stories/detail/8-things-to-know-about-pandemic-influenza. Accessed April 2020. 2. World Health Organization. Tuberculosis. Available at: https://www.who.int/health-topics/tuberculosis#tab=tab_1. Accessed May 2020. 3. European Centre for Disease Prevention and Control. Factsheet about seasonal influenza. Available at: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet. Accessed April 2020. 4. Centers for Disease Control and Prevention. Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection. Available at: https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm. Accessed April 2020. 5. Eddabra R and Ait Benhassou H. Pneumonia. 2018;10:4. Published 2018 May 25.

Contact us

to discuss how we can support your enteric testing needs